Literature DB >> 9825971

Port-A-Cath usage in children with haemophilia: experience of 53 cases.

R Ljung1, M van den Berg, P Petrini, L Tengborn, E Scheibel, R Kekomäki, W Effenberger.   

Abstract

Experience of the Port-A-Cath implantable venous access system in 53 children with severe or moderate haemophilia A or B from seven centres in five countries is reviewed. The cumulative duration of follow-up was 1578 months (median 30 months, range 1-114). Of the devices implanted, 70% (37/53) were used without complications (median follow-up 32 months; range 1-114) and the remaining 30% (16/53) were associated with various types of complication: infection, bacteraemia or septicaemia in 56% (9/16) of cases, i.e. a rate of 0.07 per follow-up year or 0.19 per 1000 patient days, or various technical complications occurring after a median of 32 months (range 4-75) of uncomplicated use in the remaining 44% (7/16). Of the patients with inhibitors, 64% (7/11) manifested complications. Both doctors and parents considered that the Port-A-Cath device can be used with an acceptable frequency and severity of complications, and that it enables regular prophylactic or on-demand home treatment of children with haemophilia to be begun at an early age.

Entities:  

Mesh:

Year:  1998        PMID: 9825971     DOI: 10.1080/080352598750031365

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  4 in total

Review 1.  Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.

Authors:  Elena Santagostino; Maria Elisa Mancuso
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

2.  Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.

Authors:  Eeva Piitulainen; Elisabeth Bernspång; Sven Björkman; Erik Berntorp
Journal:  Eur J Clin Pharmacol       Date:  2003-05-01       Impact factor: 2.953

Review 3.  Treatment strategies in children with hemophilia.

Authors:  Pia Petrini
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Barriers and perceived limitations to early treatment of hemophilia.

Authors:  Kapil Saxena
Journal:  J Blood Med       Date:  2013-05-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.